Good morning: Emma Walmsley has been busy since becoming chief executive of Glaxosmithkline in April. The former head of Glaxo’s consumer healthcare division has announced a “strategic review” of its cephalosporins antibiotics division and ditched a plan to spend £350 million building a biopharmaceuticals facility in Ulverston. She has also announced the sale of the Horlicks brand in the UK and the closure of the factory in Slough where the drink was first made in 1908. It is a big moment for Britain’s largest drugs group. Alex Ralph, our GSK watcher, will have a story later…

Source: The Times July 26, 2017 07:52 UTC